Ensemble Therapeutics Forms Global Strategic Collaboration for Development of Oral, Macrocyclic IL-17 Antagonists and Additional Disease Targets

Ensemble Therapeutics Forms Global Strategic Collaboration for Development of Oral, Macrocyclic IL-17 Antagonists and Additional Disease Targets

August 6, 2013

Collaboration to Accelerate Ensemble’s Novel, Oral, Interleukin-17 Inhibitor Program, and to Leverage Ensemble’s Innovative Drug Discovery Chemistry Platforms Against Certain Other Targets

PharmaVOICE Magazine Announces the 2013 PharmaVOICE 100

PharmaVOICE Magazine Announces the 2013 PharmaVOICE 100

August 1, 2013

TITUSVILLE, NJ, Aug 01, 2013 (Marketwired via COMTEX) -- Established nine years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life-sciences industry.

Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development

Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development

July 31, 2013

/PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Joseph Bolen, Ph.D., joined Moderna as its president of research and development (R&D).

Quanterix Announces Commercial Availability of its Simoa Single Molecule Array Technology

Quanterix Announces Commercial Availability of its Simoa Single Molecule Array Technology

July 30, 2013

Ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1,000 times lower than the best immunoassays is now commercially available for biomedical research

BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Non-Small Cell Lung Cancer

BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Non-Small Cell Lung Cancer

July 29, 2013

One of Two Phase 2 Clinical Studies with BIND-014

Agios Pharmaceuticals Prices Initial Public Offering

Agios Pharmaceuticals Prices Initial Public Offering

July 23, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Agios Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 5,888,888 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Agios. In addition, Agios has granted the underwriters a 30-day option to purchase up to 883,333 additional shares of common stock from Agios at the public offering price, less the underwriting discount.

Receptos Announces Appointment of Erle T. Mast as Director

Receptos Announces Appointment of Erle T. Mast as Director

July 22, 2013

Ensemble Therapeutics and Alexion Initiate Collaboration to Discover Macrocycle Drug Candidates Targeting Patients with Severe and Ultra-Rare Disorders

Ensemble Therapeutics and Alexion Initiate Collaboration to Discover Macrocycle Drug Candidates Targeting Patients with Severe and Ultra-Rare Disorders

July 18, 2013

Goal of Discovering Small Molecule Drug Candidates for Worldwide Development and Commercialization by Alexion

FDA Grants QIDP Designation to Eravacycline, Tetraphase’s Lead Antibiotic Product Candidate

FDA Grants QIDP Designation to Eravacycline, Tetraphase’s Lead Antibiotic Product Candidate

July 15, 2013

WATERTOWN, Mass.--()--

Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer

Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer

July 15, 2013

--Company to Accelerate Product Development based on Novel Antibody Platform focused on Infectious Diseases--